Approval ratings for the coronavirus response from President Trump and the Centers for Disease Control are dipping, a new poll released by Morning Consult on Monday shows.
Of those surveyed, 49 percent approved of the job Trump is doing to prepare the U.S. for the virus, which is down 7 percent from the previous week's poll and 12 percent from earlier this month. His disapproval rating, meanwhile, jumped up from 27 percent to 37 percent.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Ozempic can curb alcohol cravings, study findsSpeed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
-
How Trump's executive orders are threatening scientific researchIn the spotlight Agencies are purging important health information
-
New form of H5N1 bird flu found in US dairy cowsSpeed Read This new form of bird flu is different from the version that spread through herds in the last year
-
Microplastics accumulating in human brains, study findsSpeed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
-
FDA approves painkiller said to thwart addictionSpeed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
-
Study finds possible alternative abortion pillSpeed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
-
HMPV is spreading in China but there's no need to worryThe Explainer Respiratory illness is common in winter
-
Marty Makary: the medical contrarian who will lead the FDAIn the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
